NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.
You may also be interested in...
U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails
The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.
Xarelto And Pradaxa Stumble At High U.K. Reimbursement Hurdles
NICE issues draft rejection of Bayer's blood thinner Xarelto for use in preventing stroke associated with atrial fibrillation, while a U.K. payer fights a positive recommendation for Boehringer Ingelheim's Pradaxa in the same indication.
U.K. Industry Promotes Real World Data As Backbone Of Value-Based Purchasing, Despite Government Lethargy
The U.K. government has sidelined the VBP debate, preferring to focus on other aspects of health care reform, but industry is pressing ahead with its vision for pricing and reimbursement evaluation.